Took my first shot 1mg today only noticed a faster heart rate similar to when I started Reta. Will report my progress.

Glow family, let’s talk about a name you may be hearing more often: ELORALINTIDE. 💛 Quick naming update: we have renamed our listing on glowglps.com “Ellie.” Eloralintide is still the scientific name to use when looking up the research. Ellie is our site’s name, not an approved medicine brand or a Lilly endorsement. 🧠 WHAT IS IT? Eloralintide is an investigational selective amylin receptor agonist. In plain English, researchers are studying how it activates a pathway involved in feeling full. It works through a different receptor pathway from GLP-1 medicines. 🔬 WHY THE INTEREST? In a 48-week Phase 2 trial involving 263 adults with obesity or overweight and a related health condition, without type 2 diabetes, eloralintide groups had average weight reductions ranging from 9.5% to 20.1%, versus 0.4% with placebo. Those results were published in The Lancet in 2025. Gastrointestinal symptoms and fatigue were the most common adverse events. 📰 THE LATEST HEADLINE — SEPTEMBER 30, 2026 Lilly reported a separate 48-week Phase 2b study in 367 adults with obesity or overweight AND type 2 diabetes. The highest-dose eloralintide-plus-tirzepatide group had an average 23.3% weight reduction, compared with 14.8% for tirzepatide alone. That 23.3% figure is for the COMBINATION—not eloralintide alone. The headline percentages above use an analysis estimating results if participants remained on treatment; they are not guaranteed individual outcomes. ⚖️ WHAT ELSE SHOULD WE KNOW? In the combination study, gastrointestinal side effects were more frequent with the combination. Across combination groups, 10.8%–27.0% stopped treatment because of adverse events, versus 2.9% with tirzepatide alone. That matters alongside the weight-loss headline. Eloralintide remains investigational, with Phase 3 studies underway. Longer-term safety and effectiveness still need study. These trials evaluated Lilly’s study medicine; they do not establish the identity, quality, safety, or effectiveness of a product sold under the name Ellie.

Today was my first day trying kisspeptin, and I wanted to share how I felt: wonderful, incredibly happy, and uplifted in spirit. 💗 That feeling of “I feel really good today” is something I want to pause and appreciate. We talk so much about physical changes, but feeling happy within yourself deserves a little celebration, too. One day can’t tell me whether kisspeptin caused that feeling, so I’m keeping an open mind and sharing my personal experience as it unfolds. Today, I felt wonderful—and I’m grateful for it. ✨

You have seen it all over the news and at a 27% weightloss, anyone in a stall will LOVE this! Imagine your body is a house, and your brain is the person controlling the kitchen. When you eat, your body sends messages to your brain saying things like: - "I'm hungry!" - "I'm getting full." - "Okay, I've had enough food!" One of the natural messengers involved in telling your brain you're full is a hormone called amylin. Your pancreas releases amylin along with insulin when you eat. Eloralintide is designed to act like amylin. Scientists call it a long-acting amylin receptor agonist. That's a fancy way of saying it activates some of the same cellular switches as your body's natural amylin. It won't last. glowglps.comhttps://www.glowglps.com

You asked. We restocked. MOTS-C is officially back at GlowGLPS.com! 🎉 If MOTS-C has been on your list, now is your chance to grab it. Inventory can move fast, so don’t wait too long. 🛒 Shop now: https://GlowGLPS.com Drop a ⚡ below if you’ve been waiting for this restock! For research use only. Not for human consumption.